Page 62 - TD-1-1

Tumor Discovery Anti-PD1 for advanced pancreatic cancer

(2018000026833ZK78), and Xuanwu Hospital Huizhi 5. Li D, Yeung SC, Hassan MM, et al., 2009, Antidiabetic
Talent Project (XW2019091680124). therapies affect risk of pancreatic cancer. Gastroenterology,
137(2): 482–488.
Conflict of interest https://doi.org/10.1053/j.gastro.2009.04.013

The authors report no conflict of interest. 6. Blackford A, Parmigiani G, Kensler TW, et al., 2009, Genetic
mutations associated with cigarette smoking in pancreatic
Author contributions cancer. Cancer Res, 69(8): 3681–3688.
Conceptualization: Hongyan Li 7. Moore MJ, Goldstein D, Hamm J, et al., 2007, Erlotinib plus
Data curation: Zhe Jiang gemcitabine compared with gemcitabine alone in patients
with advanced pancreatic cancer: a phase III trial of the
Supervision: Fei Li National Cancer Institute of Canada clinical trials group.
J Clin Oncol, 25(15): 1960–1966.
Writing - original draft: Zhe Jiang
https://doi.org/10.1200/jco.2005.23.16_suppl.1
Writing - review & editing: Hongyan Li
8. Sun J, Wan Z, Chen Y, et al., 2020, Triple drugs
Ethics approval and consent to participate co-delivered by a small gemcitabine-based carrier for PC
immunochemotherapy. Acta Biomater, 106: 289–300.
This research was approved by the Ethics Committee of The
Xuan Wu Hospital (No. 2020027). The patient described in https://doi.org/10.1016/j.actbio.2020.01.039
this study has given his informed consent to participate in 9. Wu D, Lv J, Zhao R, et al., 2020, PSCA is a target of chimeric
this study. antigen receptor T cells in gastric cancer. Biomark Res, 8: 3–16.
https://doi.org/10.1186/s40364-020-0183-x
Consent for publication
10. Gautam SK, Kumar S, Dam V, et al., 2020, MUCIN-4
Informed consent has been obtained from the patient for (MUC4) is a novel tumor antigen in PC immunotherapy.
publication of this case report. Semin Immunol, 14: 101391–101399.

References https://doi.org/10.1016/j.smim.2020.101391
11. Okusaka T, Furuse J, 2020, Recent advances in chemotherapy for
1. Raimondi S, Maisonneuve P, Lowenfels AB, 2009,
Epidemiology of pancreatic cancer: An overview. Nat Rev pancreatic cancer: Evidence from Japan and recommendations
Gastroenterol Hepatol, 6(12): 699–708. in guidelines. J Gastroenterol, 55(4): 369–382.
https://doi.org/10.1007/s00535-020-01666-y
https://doi.org/10.1038/nrgastro.2009.177
12. Schizas D, Charalampakis N, Kole C, et al., 2020,
2. Klein AP, Brune KA, Petersen GM, et al., 2004,
Prospective risk of PC in familial PC kindreds. Cancer Res, Immunotherapy for pancreatic cancer: A 2020 update.
64(7): 2634–2638. Cancer Treat Rev, 86: 102016.
https://doi.org/10.1016/j.ctrv.2020.102016
3. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al.,
2009, Genome-wide association study identifies variants in 13. Tivadar ST, McIntosh RS, Chua JX, et al., 2020, Monoclonal
the ABO locus associated with susceptibility to pancreatic antibody targeting sialyl-di-Lewis -containing internalizing
a
cancer. Nat Genet, 41(9): 986–990. and noninternalizing glycoproteins with cancer
immunotherapy development potential. Mol Cancer Ther,
4. Wolpin BM, Chan AT, Hartge P, et al., 2009, ABO blood
group and the risk of pancreatic cancer. J Natl Cancer Inst, 19(3): 790–801.
101(6): 424–431. https://doi.org/10.1158/1535-7163.mct-19-0221

Volume 1 Issue 1 (2022) 4 https://doi.org/10.36922/td.v1i1.52